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Background: Left ventricular assist devices (LVAD) are indicated as bridging or destination therapy for
patients with advanced (Stage D) heart failure and reduced ejection fraction (HFrEF). Due to the cluster-
ing of the mutual risk factors, HFrEF patients have a high prevalence of peripheral arterial disease (PAD).
This, along with the fact that continuous flow LVAD influence shear stress on the vasculature, can further
deteriorate the PAD.
Methods: We queried the National Inpatient Sample (NIS) database (2002–2014) to identify the burden of
pre-existing PAD cases, its association with LVAD, in-hospital mortality, and other complications of LVAD.
The adjusted odds ratio (aOR) and 95% confidence interval (CI) were calculated using the Cochran–Ma
ntel–Haenszel test.
Results: A total of 20,817 LVAD patients, comprising of 1,625 (7.8%) PAD and 19,192 (91.2%) non-PAD
patients were included in the study. The odds of in-hospital mortality in PAD patients were significantly
higher compared to non-PAD group (OR 1.29, CI, 1.07–1.55, P = 0.007). The PAD group had significantly
higher adjusted odds as compared to non-PAD group for acute myocardial infarction (aOR 1.29; 95% CI,
1.07–1.55, P = 0.007), major bleeding requiring transfusion (aOR, 1.286; 95% CI, 1.136–1.456, P < 0.001),
vascular complications (aOR, 2.360; 95% CI, 1.781–3.126, P < 0.001), surgical wound infections (aOR, 1.50;
95% CI, 1.17–1.94, P = 0.002), thromboembolic complications (aOR, 1.69; 95% CI, 1.36–2.10, P < 0.001),
implant-related complications (aOR, 1.47; 95% CI, 1.19–1.80, P < 0.001), and acute renal failure (aOR,
1.26; 95% CI, 1.12–1.43, P < 0.001).
Conclusion: PAD patients can have high LVAD associated mortality as compared to non-PAD.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1 Introduction
Left ventricular assist devices (LVAD) are a continuous flow ven-
tricular support device used in addition to the optimal medical
therapy (OMT) in the management of advanced heart failure
(stage-D; advanced heart failure requiring intervention) [1]. It
has two major indications in HFrEF patients, a bridge to transplant
(BTT) or destination therapy (DT). LVAD has proven benefits in
patients with circulatory failure but has also been implicated in a
variety of device-related and heart failure-related complications.
HFrEF patients receiving LVAD devices have underlying atheroscle-
rotic shares most of its risk factors and co-morbidities, including
https://doi.org/10.1016/j.ijcha.2020.100509
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old age, smoking, hypertension, diabetes mellitus, atrial fibrilla-
tion, coronary artery disease (CAD), and chronic kidney disease. It
is not uncommon for PAD to coexist with HFrEF owing to a high
prevalence of similar atherosclerotic risk factors (smoking, hyper-
lipidemia, diabetes, and hypertension) [2,3]. HFrEF patients on sec-
ond generation LVAD can have a further decline in the function of
peripheral vasculature due to a reduction in the pulsatile flow and
continuous flow-induced endothelial dysfunction. The presence of
pre-existing PAD in LVAD patients can worsen peripheral vascular
complications and is a relative contraindication for LVAD therapy
[2,4]. The 2013 International Society for Heart and Lung Transplan-
tation Guidelines for Mechanical Circulatory Support guidelines,
therefore, recommend that patients with atherosclerotic vascular
disease or significant risk factors for developing PAD should be
screened prior to the use of mechanical circulatory support (Class
IIa; Level of evidence C). 24 Despite these recommendations, the
subsequent outcomes of LVAD placement in a pre-existing PAD
have not yet been explored. Looking at the paucity of data on LVAD
and PAD, we sought to determine LVAD-related complications and
mortality in PAD patients.
2 Methods
The national inpatient sample (NIS) database is a publicly avail-
able database of ~8 million yearly discharges from non-federal hos-
pitals [5]. Due to the unidentified nature of data, our study was
exempt from institutional review board (IRB). We queried NIS
(2002–2014) using the International Classification of Disease,
Ninth Edition, Clinical Modification (ICD-9-CM) codes for PAD
(440.0–440.4 440.8, 440.9, 443.1, 443.8, 443.81, 443.82, 443.89,
443.9, 447.1, V43.4) and procedure LVAD due to HFrEF stage D with
ICD-9CM code for LVAD Heart Assist System (37.66). (supplemen-
tary table-1) The exclusion criteria included ICD-9-CM codes for
orthotopic heart transplantation (ICD codes 37.5, 37.51, and
33.6), biventricular assist device (BiVAD) implantation (ICD code
37.52) and percutaneous or non-percutaneous short-term
mechanical circulatory support (MCS) placement using codes
(37.68, 37.60, 37.62, 37.65).
The PAD and non-PAD groups were matched based on the prior
history of percutaneous coronary intervention (PCI), alcohol use
disorder, collagen vascular disease, liver disease, hypothyroidism,
lymphoma, tumors, and valvular disease. The primary outcome
of the study was in-hospital mortality. Secondary outcomes
included device-related infection including implant site wound
infection, wound dehiscence, device-related mechanical complica-
tion, conduction defects like complete heart block, respiratory
complications (pneumothorax, other iatrogenic respiratory com-
plications. postoperative aspiration pneumonia), renal complica-
tions (acute renal failure, acute renal failure requiring dialysis),
thromboembolic complications causing stroke, deep intra-organ
hemorrhage in CNS, pulmonary, gastrointestinal, genitourinary
and major bleed requiring transfusion. (Supplementary table-2).
Continuous variables were reported as weighted mean values
and standard deviation (SD) Categorical variables were compared
using the Chi-square test, whereas continuous variables were com-
pared using independent t-tests. Univariate and multiple logistic
regression analyses were performed to analyze the association
between the LVAD and the primary and secondary outcomes in
PAD patients. The regression model was adjusted for patient demo-
graphics (age, race, and gender), urgency of procedure (elective
versus emergent), Elixhauser co-morbidities, other relevant co-
morbidities which includes; CAD, carotid artery disease, prior coro-
nary artery bypass surgery (CABG) or percutaneous coronary inter-
vention (PCI), previous TIA/stroke and smoking), patients’
insurance, socioeconomic status (SES), and hospital characteristics.
(Supplementary table-3) Linear regression models were used to
assess the length of stay (LOS). The logarithmic transformation of
LOS was performed to adjust for positively skewed data. Adjusted
odds ratio (aOR) were calculated, and p-values of less than 0.05
were considered statistically significant. Statistical analysis was
performed using SPSS v21 (IBM Corp, Armonk, NY, USA).
3 Results
3.1 Search results and demographics
A total of 20,817 patients (nationally weighted patient sample)
with stage D HFrEF who underwent LVAD placement comprising of
1,625(7.8%) PAD and 19,192 (92.2%) non-PAD patients. In a
weighted sample data, the patient demographic difference of
PAD vs. non-PAD group showed a mean age of 59.83 vs. 55.11(P <
0.001), respectively. Patients in PAD group were predominantly
men (80.6% vs 75.6%, P < 0.001), and Caucasians (72% vs 65.5%,
P < 0.001). Of all 1,625 patients with PAD who underwent LVAD,
only 2.4% underwent a heart transplant. The group differences in
PAD vs. non-PAD in terms of patient characteristics and co-
morbidities are shown in Table 1.
3.2 Pooled analysis
The adjusted odds of in-hospital mortality were significantly
higher for PAD group (24.1% vs 17.3%, aOR 1.641; 95% CI, 1.41–
1.90, P < 0.001) compared to non-PAD. There was no significant dif-
ference in the LOS between the two groups S (median LOS days 29,
range 0–53 days Vs. median 28 days, range 3–53 days, P = 0.19) on
the risk-adjusted linear regression model. (supplemental table 4)
Multiple logistic regression model used to analyze group complica-
tion differences in PAD vs non-PAD. The PAD group had signifi-
cantly higher odds as compared to non-PAD group for acute
myocardial infarction (16.7% vs 12.8% a OR, 1.291; 95% CI, 1.071–
1.555, P = 0.007), major bleeding requiring transfusion (32.9% vs
28.1% a OR, 1.286; 95% CI, 1.136–1.456, P < 0.001), vascular compli-
cations (5.4% vs 2.6% a OR, 2.360; 95% CI, 1.781–3.126, P < 0.001),
surgical wound infections (5.1% vs 4.4% a OR, 1.505; 95% CI, 1.169–
1.937, P = 0.002), thromboembolic complications (11.1% vs 7.2%
aOR, 1.695; 95% CI, 1.366–2.104, P < 0.001), implant-related com-
plications (8.4% vs 6.7% a OR, 1.468; 95% CI, 1.194–1.804,
P < 0.001), and acute renal failure (55.9% vs 50.5% a OR, 1.265;
95% CI, 1.117–1.433, P < 0.001). The rate of wound dehiscence
and mechanical complications were higher in the PAD group as
compared to non-PAD group, but the difference was not statisti-
cally significant (1.2% vs 0.9%, P = 0.97) and (3% vs 2.8%,
P = 0.23), respectively (Fig. 1). The temporal trends in LVAD utiliza-
tion in PAD have been noticed to be increasing over the study per-
iod (Fig. 2).
An adjusted odds ratio (aOR) was calculated to control for the
impact of differences in the comorbidities and demographics on
the overall mortality. The aOR of mortality appears to be signifi-
cantly higher in patients with PAD undergoing device implantation
when adjusted for congestive heart failure (aOR 1.5, 95% CI 1.0–2.3,
p=<0.0001), coagulopathy (aOR 1.5, 95% CI 1.3–1.6, p=<0.0001),
hypertension (aOR 1.03, 95% CI 1.03–1.25, p = 0.008), liver disease
(aOR 1.6, 95% CI 1.3–1.9, p=<0.0001), paralysis (aOR 2.2, 95% 1.7–
2.9, p < 0.0001) and rheumatoid arthritis (aOR 1.3, 95% CI 1.9–
2.7, p < 0.0001). The detailed determinants of mortality and regres-
sion coefficients are given in the Supplementary table 5.
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4 Discussion
This is the first known largest comparison of outcomes of LVAD
in patients with and without PAD by using the NIS database (2002–
2014). In this large contemporary analysis, we observed: (1) PAD
patients who underwent LVAD have higher co-morbidities com-
pared with patients without PAD. (2) Patients with PAD who
received LVAD were at increased risk for in-hospital mortality
and complications compared to those without PAD. (3) In the
matched analysis, PAD patients have a higher likelihood of devel-
oping cardiac, vascular, renal, and surgical complications as com-
pared to non-PAD. (4) The national utilization of LVAD has been
significantly increased in recent years.
LVAD improves the quality of life (QoL), functional capacity, and
mortality in HFrEF patients. 1 Over the last decade, the survival of
HF has significantly improved secondary to LVAD implantation
with a rapidly evolving technology, enhanced procedural and
patient selection guidelines, multidisciplinary approach, and
improved perioperative care [2,4]. However, further identification
of manageable co-morbidities that impact outcomes following
LVAD implantation is needed. The presence of PAD is known to
be associated with adverse cardiovascular outcomes of LVAD
patients [6–8]. PAD represents a complex co-morbidity in patients
with refractory heart failure who undergo LVAD implantation.
These patients are known to have higher rates of in-hospital mor-
tality such as; myocardial infarction, major bleeding, vascular com-
plications, thromboembolic complications, and acute kidney injury
compared to those without PAD [6,9]. PAD, therefore, is considered
a relative contraindication for heart transplantation, especially
when it limits the rehabilitation process, and revascularization is
not an option [10]. This explains why only 2.9% of the total
22,318 heart transplant recipients and 11.05% of the total LVAD
patients had a diagnosis of PAD, in the international heart and lung
transplant registry (2006 and 2012) and Medicare database study
(total of 2,152 recipients between 2004 and 2011) [11,12]. Our
study further revealed the declining trend of these population, only
7.8% out of 20,817 LVAD patients had a diagnosis of PAD. (Fig. 3)
These results indicate that despite a high prevalence of PAD in
HFrEF patients, there is a hesitancy for these patients to have LVAD
implantation.
Patients with PAD undergoing LVAD implantation are at a
higher risk of in-hospital and out-hospital mortality. The eighth
annual report of the Interagency Registry for Mechanically Assisted
Circulatory Support (INTERMACS) reported 22,866 patients with
LVAD implantation between June 23, 2006, and December 31,
2016. Follow up data of this population show that the presence
of PAD increased both early and late mortality [13]. Similarly,
orthotopic heart transplant recipients with symptomatic PAD also
have lower survival rates compared with those without PAD [14].
Our findings are consistent with these studies, and significantly
higher mortality in the PAD group raises concerns about the safety
of LVAD in these patients. It also highlights the importance of
timely identification and management of PAD, especially if patients
have HFrEF and would be requiring an LVAD.
Our study also shows a significant burden of associated co-
morbidities in patients having PAD and LVAD. These patients are
at an increased risk for major bleeding events. Previous studies also
have reported higher HAS-BLED scores in the PAD group as com-
pared to non-PAD [15]. Both PAD and CAD have similar risk factors.
Therefore, it is common to have concomitant PAD in advanced
heart failure patients with LVAD device [16,17]. Patients with
LVAD need to anticoagulated to prevent the risk of device throm-
bosis. These patients, if started an antiplatelet for associated CAD,
can potentially worsen the risk of bleeding in these patients [18].
In addition to anticoagulation, critical limb ischemia is an indepen-
dent factor associated with major bleeding in patients with PAD
[19]. Ironically, PAD in LVAD patients also increases the risk of
thrombosis. Further factors than increase the prevalence of vascu-
lar complications include multiple secondary co-morbidities and
atherosclerotic risk factors. These observations explain the signifi-
cantly higher odds of major bleeding, thrombosis, and vascular
Table 1
Left ventricular assist device patients’ characteristics stratified by peripheral arterial
disease and non-peripheral arterial disease status.
Variable PAD No PAD P-
Value
Age 59.8 ± 12.4 55.1 ± 14.6 <0.001
Female 19.4% 24.4% <0.001
Carotid artery disease 2.3% 0.5% <0.001
Coronary artery disease 33.3% 46.2% <0.001
Prior Percutaneous coronary
intervention.
3.6% 4.0% 0.547
Prior Coronary artery bypass surgery 7.3% 3.8% <0.001
Smoking 4.1% 2.9% 0.010
HIV 0.3% 0.1% 0.041
Alcohol Abuse 2.9% 2.2% 0.062
Deficiency Anemia 21.2% 18.7% 0.014
Rheumatoid arthritis/Collagen
vascular disease
1.2% 1.0% 0.369
Chronic Blood Loss Anemia 1.5% 1.8% 0.378
Chronic Lung Disease 26.0% 16.5% <0.001
Coagulopathy 46.1% 33.2% <0.001
Depression 11.0% 9.0% 0.007
Diabetes mellitus, Uncomplicated 27.0% 22.2% <0.001
Diabetes mellitus, Complicated 8.7% 6.3% <0.001
Drug Abuse 0.6% 2.0% <0.001
Hypertension 48.0% 39.1% <0.001
Hypothyroidism 11.0% 9.6% 0.073
Liver Disease 2.4% 3.2% 0.080
Metastatic Cancer 0.3% 0.2% 0.185
Fluid and Electrolyte disorders 61.5% 57.7% 0.003
Obesity 9.0% 13.5% <0.001
Renal Failure 41.8% 32.4% <0.001
Solid Tumor Without Metastasis 1.2% 0.8% 0.087
Pulmonary Circulation Disorders 0.6% 0.3% 0.122
Psychosis 2.4% 2.6% 0.679
Peptic Ulcer Disease 0.0% 0.0% 1.000
Valvular Disease 0.3% 0.4% 0.833
Race <0.001
White 72.0% 65.5%
Black 16.1% 22.2%
Hispanic 6.5% 6.2%
Asian or Pacific Islander 1.1% 1.9%
Native American 0.0% 0.3%
Other 4.3% 4.3%
Elective hospitalization 34.5% 32.7% 0.152
Primary expected payer <0.001
Medicare 54.4% 43.5%
Medicaid 9.0% 11.8%
Private Insurance 32.4% 39.9%
Self-Pay 0.6% 1.6%
No Charge 0.3% 0.1%
Other 3.3% 3.1%
Median Household Income 0.181
0 to 25 percentiles 25.4% 25.8%
26 to 50 percentiles 25.9% 24.7%
51 to 75 percentiles 26.8% 25.4%
76 to 100 percentiles 22.0% 24.1%
Bed Size 0.039
Small 1.1% 1.6%
Medium 8.1% 9.6%
Large 90.8% 88.8%
Location/Teaching Status 0.064
Rural 0.3% 0.4%
Urban Non-teaching 5.3% 4.1%
Urban Teaching 94.4% 95.5%
Hospital Region <0.001
Northeast 14.7% 19.9%
Midwest 31.4% 29.1%
South 38.6% 34.0%
West 15.3% 17.0%
Abbreviations: PAD: Peripheral arterial disease.
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complications in the PAD-LVAD group seen in our study. Our
study also indicates a substantial increase in the odds of MI in
PAD patients with LVAD. As expected, PAD is a coronary artery
equivalent, which underscores the importance of aggressive treat-
ment of PAD patients [20]. Interestingly, the prevalence of stable
CAD was reduced in PAD patients due to a high number of coro-
nary artery bypass graft (CABG) procedures during the LVAD
implantation.
Our study closes the gaps between the clinical practice and the
said recommendations. We have identified the burden and compli-
cations of PAD in LVAD patients. We suggest that due to increased
morbidity and mortality associated with PAD, the screening pro-
cess of these patients prior to LVAD implantation should be re-
emphasized. Screening for PAD using Doppler ultrasound following
LVAD implantation is difficult due to changes in the waveforms
driven by the continuous arterial flow pattern generated by the
LVAD [21]. Recently computational flow analysis has been used
to study PAD in patients with continuous-flow LVAD, which has
shown promising results as compared to Doppler ultrasound
[21]. It is unclear if endovascular or surgical revascularization will
improve outcomes in this population.
Our study has several limitations. This is a retrospective analy-
sis of cross-sectional data of NIS, so it is difficult to draw a causal
relationship between PAD and LVAD complications. Unmeasured
confounders would have occurred in assessing the severity and eti-
ology of HF. A subgroup analysis on follow up duration could not
be done as the data represents a snapshot of the in-hospital course.
Due to the retrospective cross-sectional nature of the study and
limited applicability of the ICD coding the INTERMACS classifica-
tion for advanced heart failure could not be performed.
Fig. 1. Outcomes of left ventricular assist device surgery in patients with and without peripheral arterial disease.
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Fig. 2. Utilization of LVAD over the study period.
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5 Conclusion
Patients with PAD and LVAD had higher odds of in-hospital
mortality and morbidity compared to those without PAD.
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